Gilead To Acquire YM BioSciences
Gilead Sciences Inc. (Nasdaq: GILD) announced that it would acquire YM BioSciences Inc. (NYSE: YMI), a developer of a treatment for progressive, chronic bone marrow disorder, in an all-cash deal valued at approximately $500 million. Shares of YM BioSciences leaped $1.25 to $2.88 while Gilead stock edged up 26 cents to $76.60.

Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here